Senior Medical Science Liaison (Mid-Atlantic)

United States Req #285
Wednesday, June 19, 2024
Who We Are:  
 
Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. 
 
What We Do: 
 
We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship azetukalner program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our Phase 3 epilepsy program includes multiple clinical trials evaluating azetukalner in patients with focal onset seizures and primary generalized tonic-clonic seizures. In 2024, we are planning to initiate a Phase 3 azetukalner program in major depressive disorder, based on topline data from our Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. 

About the Role:

We are seeking a Senior Medical Science Liaison (Senior MSL) - this is an opportunity to join Xenon in a field-facing role and to help shape the development of the MSL function and team within wider Medical Affairs and Clinical Development teams. This role will engage with external Health Care Providers, Key Opinion Leaders, and patient groups to provide education on the benefits of the Xenon’s pipeline in epilepsy. 

The Senior MSL will be responsible for the Mid-Atlantic territory, engaging with Health Care Providers and attending both major and regional congresses.

The successful candidate will have proven ability to operationalize product communication strategies and have a clear understanding of the needs of health care providers, patients and families, able to clearly communicate complex scientific and medical information in an articulate and warm manner as appropriate for the specific audience. Preferred locations for this position include Philadelphia, Cleveland, and Washington, DC

RESPONSIBILITIES:
•    Build strong relationships with KOLs and other healthcare thought leaders, interacting to communicate and advance Xenon’s scientific platform, clinical and medical information in alignment with corporate and brand objectives; identify and report key scientific, clinical and research insights from KOLs to Medical Affairs and the Clinical Development and Commercial teams.
•    Act as a key scientific resource to Health Care Providers, communicate up to date medical, clinical, and scientific information about Xenon’s neurology and epilepsy products.
•    Support KOL identification and patient recruitment initiatives for assigned clinical programs in epilepsy.
•    Lead assigned national and/or regional congress activities in accordance with Medical Affairs strategies and plans.
•    Contribute to Medical Affairs and MSL strategies and plans; adapt strategies, plans, and tactics for the assigned territory.
•    Provide instruction, coaching and mentoring to new or less experienced MSLs.
•    Travel domestically up to 50% of the time, including overnight travel as business needs require. International travel may be required on an ad-hoc basis.
•    Act in accordance with Company policies, including, for example, the Code of Business Conduct and Ethics and ensure policies are understood and followed by direct reports, if any.

QUALIFICATIONS:
•    Minimum of a relevant doctorate degree (i.e. M.D., PhD, PharmD, DPH).
•    Minimum 5 years MSL experience required, with 8+ years strongly preferred.
•    Minimum 3 years MSL experience in neurology therapeutic area; experience in epilepsy strongly preferred.
•    Clinical trial development and drug launch experience strongly preferred.
•    Knowledge of clinical research processes, FDA regulations, and OIG guidelines required.
•    Ability to communicate accurately and confidently across multiple disease states.
•    Established relationships with KOLs and knowledge of institutions in neurology; epilepsy strongly preferred.
•    Excellent interpersonal and communication skills.
•    Proven ability to work both independently and cross-functionally.

The base salary range for this role is $197,400 to $210,000 USD; we will consider above this range for exceptional candidates. Base salary is determined by a combination of factors including, but not limited to, education and other qualifications, years of relevant experience, and internal equity.

Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance programs, Employee Assistance Program, travel insurance, and retirement savings programs with company matching contributions.

Xenon encourages time to rest and re-charge through vacation, personal days, sick days, and an end-of-year company shutdown. Xenon highly values employee development and has an expanding Training, Learning & Development program, including a Tuition Assistance program for advanced degrees.
 
US positions only: Xenon Pharmaceuticals USA Inc. participates in the E-Verify program in all states in which we hire. Learn more about the E-Verify program here 

To apply for this position, click Apply Now to complete the application. We thank all applicants for their interest; however, due to the volume of applicants, only those chosen for interview will be contacted.